Atara Biotherapeutics (ATRA) Other Non Operating Income (2015 - 2025)
Atara Biotherapeutics' (ATRA) quarterly Other Non Operating Income came in at -$15000.0 in Q4 2025, up 83.15% YoY from -$8190.2 in Q4 2024, and down 475.0% on a QoQ basis from $4000.0 in Q3 2025.
Atara Biotherapeutics (ATRA) Other Non Operating Income (2015 - 2025) Analysis & Trends
Atara Biotherapeutics (ATRA) has 11 years of Other Non Operating Income data on file, last reported at -$15000.0 in Q4 2025.
- Quarterly Other Non Operating Income rose 83.15% year-over-year to -$15000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $11000.0 (down 97.55% YoY) and the FY2024 annual result came in at $528000.0, up 314.63% from the prior year.
- Other Non Operating Income eased to -$15000.0 in Q4 2025, from $4000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $555000.0 in Q3 2024 to a low of -$309000.0 in Q3 2022.
- A 5-year average of -$2600.0 and a median of -$11500.0 in 2023 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 2155.56% in 2024, down 641.67% in 2024.
- Tracing ATRA's Other Non Operating Income over 5 years: stood at $84000.0 in 2021, then plunged by 182.14% to -$69000.0 in 2022, then jumped by 82.61% to -$12000.0 in 2023, then tumbled by 641.67% to -$89000.0 in 2024, then soared by 83.15% to -$15000.0 in 2025.
- The last three Other Non Operating Income figures came in at -$15000.0 (Q4 2025), $4000.0 (Q3 2025), and $22000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | -89,000.00 |
| Sep 30, 2024 | 555,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | 68,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | -27,000.00 |
| Jun 30, 2023 | -10,000.00 |
| Mar 31, 2023 | -197,000.00 |
| Dec 31, 2022 | -69,000.00 |
| Sep 30, 2022 | -309,000.00 |
| Jun 30, 2022 | -214,000.00 |
| Mar 31, 2022 | -109,000.00 |
| Dec 31, 2021 | 84,000.00 |
| Sep 30, 2021 | 148,000.00 |
| Jun 30, 2021 | 225,000.00 |
| Mar 31, 2021 | -90,000.00 |